Fox Run Management L.L.C. acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,800 shares of the company’s stock, valued at approximately $325,000.
Several other institutional investors have also recently modified their holdings of LLY. CAPROCK Group Inc. grew its position in Eli Lilly and by 17.5% during the third quarter. CAPROCK Group Inc. now owns 10,610 shares of the company’s stock worth $908,000 after buying an additional 1,583 shares during the period. Alpha Cubed Investments LLC purchased a new stake in shares of Eli Lilly and in the third quarter valued at about $302,000. Carnick & Kubik Group LLC purchased a new stake in shares of Eli Lilly and in the third quarter valued at about $2,283,000. Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its holdings in shares of Eli Lilly and by 4.7% in the third quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 47,308 shares of the company’s stock valued at $4,047,000 after purchasing an additional 2,126 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Eli Lilly and by 4.0% in the third quarter. Fisher Asset Management LLC now owns 3,109,012 shares of the company’s stock valued at $265,945,000 after purchasing an additional 119,491 shares in the last quarter. Institutional investors and hedge funds own 76.43% of the company’s stock.
A number of equities analysts have weighed in on the stock. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reissued an “underperform” rating and issued a $71.00 price objective (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and raised their price target for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $90.25.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 EPS. equities research analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.43%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the transaction, the insider now owns 123,513,247 shares of the company’s stock, valued at approximately $10,515,917,849.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 592,003 shares of company stock worth $50,246,641 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Fox Run Management L.L.C. Takes Position in Eli Lilly and Company (LLY)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/12/05/fox-run-management-l-l-c-takes-position-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.